Ferumoxytol-enhanced MRI for surveillance of pediatric cerebral arteriovenous malformations

被引:6
|
作者
Huang, Yuhao [1 ]
Singer, Timothy G. [1 ]
Iv, Michael [2 ]
Lanzman, Bryan [2 ]
Nair, Siddharth [1 ]
Stadler, James A., III [5 ]
Wang, Jia [3 ]
Edwards, Michael S. B. [1 ]
Grant, Gerald A. [1 ]
Cheshier, Samuel H. [4 ]
Yeom, Kristen W. [2 ]
机构
[1] Stanford Univ, Lucile Packard Childrens Hosp, Sch Med, Div Pediat Neurosurg, Stanford, CA 94305 USA
[2] Stanford Univ, Lucile Packard Childrens Hosp, Sch Med, Dept Radiol, Stanford, CA 94305 USA
[3] Stanford Univ, Environm Hlth & Safety, Stanford, CA 94305 USA
[4] Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT USA
[5] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurosurg, Madison, WI USA
关键词
arteriovenous malformation; arterial spin labeling; perfusion; MRI; AVM; ASL; DSA; ferumoxytol; vascular disorders; RADIATION-EXPOSURE; BRAIN; ANGIOGRAPHY; CHILDREN; SAFETY; RISK;
D O I
10.3171/2019.5.PEDS1957
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE Children with intracranial arteriovenous malformations (AVMs) undergo digital DSA for lesion surveillance following their initial diagnosis. However, DSA carries risks of radiation exposure, particularly for the growing pediatric brain and over lifetime. The authors evaluated whether MRI enhanced with a blood pool ferumoxytol (Fe) contrast agent (Fe-MRI) can be used for surveillance of residual or recurrent AVMs. METHODS A retrospective cohort was assembled of children with an established AVM diagnosis who underwent surveillance by both DSA and 3-T Fe-MRI from 2014 to 2016. Two neuroradiologists blinded to the DSA results independently assessed Fe-enhanced T1-weighted spoiled gradient recalled acquisition in steady state (Fe-SPGR) scans and, if available, arterial spin labeling (ASL) perfusion scans for residual or recurrent AVMs. Diagnostic confidence was examined using a Likert scale. Sensitivity, specificity, and intermodality reliability were determined using DSA studies as the gold standard. Radiation exposure related to DSA was calculated as total dose area product (TDAP) and effective dose. RESULTS Fifteen patients were included in this study (mean age 10 years, range 3-15 years). The mean time between the first surveillance DSA and Fe-MRI studies was 17 days (SD 47). Intermodality agreement was excellent between FeSPGR and DSA (kappa = 1.00) but poor between ASL and DSA (kappa = 0.53; 95% CI 0.18-0.89). The sensitivity and specificity for detecting residual AVMs using Fe-SPGR were 100% and 100%, and using ASL they were 72% and 100%, respectively. Radiologists reported overall high diagnostic confidence using Fe-SPGR. On average, patients received two surveillance DSA studies over the study period, which on average equated to a TDAP of 117.2 Gyxcm(2) (95% CI 77.2-157.4 Gyxcm(2)) and an effective dose of 7.8 mSv (95% CI 4.4-8.8 mSv). CONCLUSIONS Fe-MRI performed similarly to DSA for the surveillance of residual AVMs. Future multicenter studies could further investigate the efficacy of Fe-MRI as a noninvasive alternative to DSA for monitoring AVMs in children.
引用
收藏
页码:407 / 414
页数:8
相关论文
共 50 条
  • [21] Improved Detection of Bone Metastases in Children and Young Adults with Ferumoxytol-enhanced MRI
    Rashidi, Ali
    Baratto, Lucia
    Theruvath, Ashok Joseph
    Greene, Elton Benjamin
    Jayapal, Praveen
    Hawk, K. Elizabeth
    Lu, Rong
    Seekins, Jayne
    Spunt, Sheri L.
    Pribnow, Allison
    Daldrup-Link, Heike E.
    RADIOLOGY-IMAGING CANCER, 2023, 5 (02):
  • [22] Ferumoxytol-enhanced MRI of retroplacental clear space disruption in placenta accreta spectrum
    Badachhape, Andrew A.
    Burnett, Brian
    Bhandari, Prajwal
    Devkota, Laxman
    Bhavane, Rohan
    Menon, Renuka
    Srivastava, Mayank
    Lombaard, Hennie
    Shamshirsaz, Amir
    Ghaghada, Ketan B.
    Fox, Karin A.
    Annapragada, Ananth, V
    PLACENTA, 2025, 160 : 100 - 106
  • [23] Unveiling the next generation of MRI contrast agents:current insights and perspectives on ferumoxytol-enhanced MRI
    Guangxiang Si
    Yue Du
    Peng Tang
    Gao Ma
    Zhaochen Jia
    Xiaoyue Zhou
    Dan Mu
    Yan Shen
    Yi Lu
    Yu Mao
    Chuan Chen
    Yan Li
    Ning Gu
    National Science Review, 2024, 11 (05) : 385 - 404
  • [24] Unveiling the next generation of MRI contrast agents: current insights and perspectives on ferumoxytol-enhanced MRI
    Si, Guangxiang
    Du, Yue
    Tang, Peng
    Ma, Gao
    Jia, Zhaochen
    Zhou, Xiaoyue
    Mu, Dan
    Shen, Yan
    Lu, Yi
    Mao, Yu
    Chen, Chuan
    Li, Yan
    Gu, Ning
    NATIONAL SCIENCE REVIEW, 2024, 11 (05)
  • [25] Measurements of cerebral blood volume using quantitative susceptibility mapping, R2* relaxometry, and ferumoxytol-enhanced MRI
    Rivera-Rivera, Leonardo A.
    Schubert, Tilman
    Johnson, Kevin M.
    NMR IN BIOMEDICINE, 2019, 32 (12)
  • [26] Ferumoxytol-Enhanced MRI Is Not Inferior to Gadolinium-Enhanced MRI in Detecting Intracranial Metastatic Disease and Metastasis Size
    Hamilton, Bronwyn E.
    Barajas, Ramon
    Nesbit, Gary M.
    Fu, Rongwei
    Ambady, Prakash
    Taylor, Matthew
    Neuwelt, Edward A.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2020, 215 (06) : 1436 - 1442
  • [27] Measurement of microvascular cerebral blood volume changes over the cardiac cycle with ferumoxytol-enhanced T2* MRI
    Rivera-Rivera, Leonardo A.
    Johnson, Kevin M.
    Turski, Patrick A.
    Wieben, Oliver
    Schubert, Tilman
    MAGNETIC RESONANCE IN MEDICINE, 2019, 81 (06) : 3588 - 3598
  • [28] Surveillance of Residual Pediatric Brain Arteriovenous Malformations Using Ferumoxytol-based ASL and SPGR Magnetic Resonance Series
    Huang, Yuhao
    Singer, Timothy
    Iv, Michael
    Lanzman, Bryan
    Stadler, James, III
    Wang, Jia
    Grant, Gerald
    Cheshier, Samuel
    Yeom, Kristen
    JOURNAL OF NEUROSURGERY, 2019, 131 (01)
  • [29] Tracking Stem Cell Implants in Cartilage Defects of Minipigs by Using Ferumoxytol-enhanced MRI
    Theruvath, Ashok J.
    Nejadnik, Hossein
    Lenkov, Olga
    Yerneni, Ketan
    Li, Kai
    Kuntz, Lara
    Wolterman, Cody
    Tuebel, Jutta
    Burgkart, Rainer
    Liang, Tie
    Felt, Stephen
    Daldrup-Link, Heike E.
    RADIOLOGY, 2019, 292 (01) : 129 - 137
  • [30] Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer
    Ravi, Harshan
    Arias-Lorza, Andres M.
    Costello, James R.
    Han, Hyo Sook
    Jeong, Daniel K.
    Klinz, Stephan G.
    Sachdev, Jasgit C.
    Korn, Ronald L.
    Raghunand, Natarajan
    RADIOLOGY-IMAGING CANCER, 2023, 5 (02):